Want to see HK:6185 full AI Analyst Report?
6185 Stock Chart & Stats
HK$44.94
-HK$0.10(-0.36%)
At close: 4:00 PM EST
HK$44.94
-HK$0.10(-0.36%)
Day’s Range― - ―
52-Week RangeHK$19.22 - HK$56.55
Previous CloseN/A
Volume470.05K
Average Volume (3M)609.75K
Market Cap
HK$9.76B
Enterprise ValueHK$6.66K
Total Cash (Recent Filing)HK$2.07B
Total Debt (Recent Filing)HK$1.16B
Price to Earnings (P/E)1684.2
Beta1.51
Next Earnings
Aug 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.66
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.40Price Target Upside16.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.42
Revenue Forecast (FY)HK$1.43B
Bulls Say, Bears Say
Bulls Say
Integrated R&D-to-manufacturing CapabilityOwning end-to-end vaccine capabilities (R&D through manufacturing and commercialization) is a durable competitive advantage. It reduces dependence on external CDMOs, supports faster scale-up for demand surges, preserves margins and IP control, and enables coordinated product life-cycle management.
Multi-disease Product PortfolioA portfolio spanning marketed and pipeline vaccines across multiple disease areas diversifies revenue sources and clinical risk. This structural diversification supports more stable long-term revenue potential and provides multiple commercialization pathways as individual programs progress.
Moderate Leverage / Relatively Solid Balance SheetDebt-to-equity near 0.26 indicates moderate leverage and meaningful equity cushion. This balance sheet flexibility supports ongoing R&D and capacity investments, reduces refinancing risk, and gives management room to fund strategic initiatives without immediate pressure from high interest burdens.
Bears Say
Negative Free Cash FlowDespite improving operating cash flow, persistent negative free cash flow means the company still burns cash after investments. Over the medium term this necessitates external financing or asset sales to fund growth, constraining self-funded expansion and increasing financing risk.
Fragile, Volatile ProfitabilityEarnings have swung from strong profitability in 2021 to deep losses in 2022–2023 and only marginal improvement recently. This volatility and thin margins reduce predictability of returns, limit reinvestment capacity and make long-term earnings projections uncertain.
Revenue Exposure To Procurement/tender TimingReliance on procurement and tender-based sales creates structural revenue timing and volume risk, and subjects pricing to competitive bids. This dependency can compress margins, produce lumpy revenue recognition and make multi-quarter demand visibility weak for strategic planning.
CanSino Biologics, Inc. Class H News
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$19.22 and its highest was HK$56.55 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$9.76B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 27 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Apr 28, 2026. The company reported -HK$0.186 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Undervalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of -HK$0.186 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.805%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
6185 Stock 12 Month Forecast
Average Price Target
HK$52.40
▲(16.60% Upside)
Technical Analysis
HUTCHMED (China)
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ab&B Bio-Tech CO., LTD. JS Class H
―
Xuanzhu Biopharmaceutical Co., Ltd. Class H
―